SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking...
Earnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented...
About Atossa Genetics Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
Shareholders of $MACK are getting a $20 million special dividend. The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date. Stockholders of record on the record date who...
EnWave will likely be one of the key hidden gems in the biotechnological industry and will continue to gain volume as time progresses. Their company focuses on a multitude of revenue streams for dehydration techniques (patented) and has several revenue streams including royalty bearing and selling their equipment to other companies. This is one of the most...
Amgen is attempting a breakout above its one-month downward trend line this morning. I will wait to enter until I see a change in volume. Currently there's bearish divergence on the volume profile, which suggests that this may correct downward before confirming the breakout. Amgen reports earnings tomorrow, and has a positive earnings surprise prediction from...
- BLUE - Possible stock price improvement, based on the theory of triangles. - YELLOW - Triangle hypotenuse that can't be crossed if formation is to be completed. - RED - Triangle roof that can give a buy signal if crossed. Wanted to share with you what I found in the chart. This is not a advice to invest. Plz comment if you disagree or want to add...
Potential downside breakout for biotech. Still too early to confirm whether it's real or a fake, keep an eye on this one. Entered 25% position so far, will look to add more if further confirmation appears.
Biogen has formed an ascending triangle. With strong earnings and a guidance upgrade, the catalysts favor upward breakout. However, certain aspects of Biogen's business are struggling and face increasing competition, so the stock could also fall. I will play oscillations within the triangle by buying and selling crossovers of the green line, with stop losses in...
One of my followers asked (and this has never happened before) for me to comment on LABU. I was touched by the request and so I have responded, and this after having a website which I shut down with 10,000 hits a month never once did anyone ask me to comment on a stock. My strength has always been analysis and dissection so I am happy to oblige. LABU isn't...
Zynerba Pharmaceuticals has been surging since it got added to the Russell 2000 and 3000 indices. It is in an upward channel, just broke trendline resistance, and looks strong on the indicators, including high buying volume. It will meet short-term resistance around 16.47. Look for a break above that level on volume.
Merck ended the day near the bottom of its parallel channel, right above a high-volume support node at 8.19 and a trend line that's parallel with channel bottom. After hours, the price has moved below both the support and the trend line, but in my experience, after hours moves don't necessarily mean much. The real test will be tomorrow after market open. If the...
TDOC with great technicals. RSI(10) @60 reaching higher OBV on higher highs ADX(14) @24 DI+ > DI -
With the market down today, MDT doesn't care... It's breaking tested, heavy resistance at all time highs. Technicals look great as well. *Check chart for more info*
Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out. This marks potential accumulation range for anyone looking to build a position in EYPT. Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down. Range low/ highs, range from $1.42 -...
Galapagos announced today a large investment and a 10-year deal with Gilead $GILD. The stock gapped due to Gilead buying 10% of Galapagos at $158/share. However, when stocks gap up on investments at a premium price, they almost always fall (see $MGI, $ARWR) An analyst at Raymond James agrees, saying he believes $GLPG stock has now fully realized his price target...
AVROBIO got a good pop today from very positive Phase 2 clinical trial results from its kidney drug. Unquestionably the news was good; the drug shows strong efficacy and no adverse events. However, this was only a Phase 2 trial so there's a long way still to go in the approval process. Meanwhile, the company is losing money and is rated as an overvalued and...
Investors bought the hype surrounding SOLY's clinical trial results, and today they sold the news. SOLY fell nearly 14% despite better-than-expected results in its cellulite treatment trial. Looking at the volume profile, I think SOLY may continue to fall to the 14.00-14.50 range, and then rebound upward from there. I wouldn't enter any earlier than that.